The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes

Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1- /Hepatocyte Nuclear Factor 4-  Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes

(2011) R. E. J. Besser et al.   DIABETES CARE

Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes

(2011) T. J. McDonald et al.   DIABETIC MEDICINE

Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to HNF1A Mutations

(2010) K. R. Owen et al.   DIABETES CARE

Maturity-onset diabetes of the young (MODY): how many cases are we missing?

(2010) B. M. Shields et al.   DIABETOLOGIA

Incidence of Childhood Diabetes in Children Aged Less than 15 Years and Its Clinical and Metabolic Characteristics at the Time of Diagnosis: Data from the Childhood Diabetes Registry of Saxony, Germany

(2010) Angela Galler et al.   Hormone Research in Paediatrics

A genetic diagnosis ofHNF1Adiabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients

(2009) M. Shepherd et al.   DIABETIC MEDICINE

Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database

(2009) E. Schober et al.   DIABETIC MEDICINE

Prevalence ofHNF1A(MODY3) mutations in a Norwegian population (the HUNT2 Study)

(2008) S. . Eide et al.   DIABETIC MEDICINE

Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young

(2008) S. Ellard et al.   DIABETOLOGIA